Lannett (LCI) To Report Q3 Earnings: What's In The Cards?
Zacks Investment Research | Apr 24, 2019 04:45AM ET
During Lannett Company, Inc.’s (NYSE:LCI) fiscal first-quarter 2019 call, the focus is expected to be on product launches.
Lannett’s shares have slumped 54.4% in the past year compared with the industry ’s decline of 13%.
Let’s see how things are shaping up for this announcement.
Factors in Play
Lannett the generic pharmaceutical company launched 17 products in calendar year 2018, which are expected to contribute significantly to net sales in fiscal third-quarter 2019. The company's product launches during the quarter are expected to contribute significantly to sales. Investors’ focus will be on the launch of these products, as stated by the management earlier.
The company intends to realize $66 million in total savings with $33 million of reinvestment. In fact, a portion of these savings is expected to be realized in fiscal third-quarter 2019.
In March 2019, Lannett received approval from the FDA for its abbreviated new drug application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The drug should boost sales for the company in fiscal third quarter 2019.
What Our Model Indicates
Our proven model does not conclusively show that Lannett is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Lannett has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a profit of 62 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Zacks Rank: The company carries a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Get The News You Want
Stocks That Warrant a Look
Here are some health-care stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Pfizer Inc. (NYSE:PFE) has an Earnings ESP of +0.65% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on Apr 30. You can see .
Glaxo SmithKline plc. (NYSE:GSK) has an Earnings ESP of +1.27% and a Zacks Rank #2. The company is scheduled to release first-quarter 2019 results on May 1.
Novo Nordisk (CO:NOVOb) A/S (NYSE:NVO) has an Earnings ESP of +0.8% and a Zacks Rank #3. The company is scheduled to release its first quarter 2019 results on May 3.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.